LeMaitre initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of LeMaitre Vascular with an Outperform rating and $60 price target. The company has an “enviable track record of finding or creating niche markets” in the peripheral vascular disease market and is building up dominant market share, the analyst tells investors in a research note. The firm says LeMaitre is generating increasing profits and cash flow every year, and it expects “more of the same in years to come.”